Free Trial

Vivos Therapeutics Q3 2023 Earnings Report

Vivos Therapeutics logo
$4.98 +0.32 (+6.87%)
(As of 12/20/2024 05:45 PM ET)

Vivos Therapeutics Earnings Headlines

Wall Street Icon: “You must get on the right side of this thing”
I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.
Vivos Therapeutics Reports Revenue Growth and Strategic Milestones
See More Vivos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivos Therapeutics and other key companies, straight to your email.

About Vivos Therapeutics

Vivos Therapeutics (NASDAQ:VVOS), a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

View Vivos Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings